Your browser doesn't support javascript.
loading
Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.
de la Fuente, Macarena I; Young, Robert J; Rubel, Jennifer; Rosenblum, Marc; Tisnado, Jamie; Briggs, Samuel; Arevalo-Perez, Julio; Cross, Justin R; Campos, Carl; Straley, Kimberly; Zhu, Dongwei; Dong, Chuanhui; Thomas, Alissa; Omuro, Antonio A; Nolan, Craig P; Pentsova, Elena; Kaley, Thomas J; Oh, Jung H; Noeske, Ralph; Maher, Elizabeth; Choi, Changho; Gutin, Philip H; Holodny, Andrei I; Yen, Katharine; DeAngelis, Lisa M; Mellinghoff, Ingo K; Thakur, Sunitha B.
Afiliação
  • de la Fuente MI; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (M.I.d., S.B., A.T., A.A.O., C.P.N., E.P., T.J.K., L.M.D., I.K.M.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (R.J.Y., J.R., J.T., J.A.-P., A.I.H., S.B.T.); Department of Pat
  • Young RJ; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (M.I.d., S.B., A.T., A.A.O., C.P.N., E.P., T.J.K., L.M.D., I.K.M.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (R.J.Y., J.R., J.T., J.A.-P., A.I.H., S.B.T.); Department of Pat
  • Rubel J; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (M.I.d., S.B., A.T., A.A.O., C.P.N., E.P., T.J.K., L.M.D., I.K.M.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (R.J.Y., J.R., J.T., J.A.-P., A.I.H., S.B.T.); Department of Pat
  • Rosenblum M; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (M.I.d., S.B., A.T., A.A.O., C.P.N., E.P., T.J.K., L.M.D., I.K.M.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (R.J.Y., J.R., J.T., J.A.-P., A.I.H., S.B.T.); Department of Pat
  • Tisnado J; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (M.I.d., S.B., A.T., A.A.O., C.P.N., E.P., T.J.K., L.M.D., I.K.M.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (R.J.Y., J.R., J.T., J.A.-P., A.I.H., S.B.T.); Department of Pat
  • Briggs S; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (M.I.d., S.B., A.T., A.A.O., C.P.N., E.P., T.J.K., L.M.D., I.K.M.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (R.J.Y., J.R., J.T., J.A.-P., A.I.H., S.B.T.); Department of Pat
  • Arevalo-Perez J; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (M.I.d., S.B., A.T., A.A.O., C.P.N., E.P., T.J.K., L.M.D., I.K.M.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (R.J.Y., J.R., J.T., J.A.-P., A.I.H., S.B.T.); Department of Pat
  • Cross JR; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (M.I.d., S.B., A.T., A.A.O., C.P.N., E.P., T.J.K., L.M.D., I.K.M.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (R.J.Y., J.R., J.T., J.A.-P., A.I.H., S.B.T.); Department of Pat
  • Campos C; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (M.I.d., S.B., A.T., A.A.O., C.P.N., E.P., T.J.K., L.M.D., I.K.M.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (R.J.Y., J.R., J.T., J.A.-P., A.I.H., S.B.T.); Department of Pat
  • Straley K; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (M.I.d., S.B., A.T., A.A.O., C.P.N., E.P., T.J.K., L.M.D., I.K.M.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (R.J.Y., J.R., J.T., J.A.-P., A.I.H., S.B.T.); Department of Pat
  • Zhu D; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (M.I.d., S.B., A.T., A.A.O., C.P.N., E.P., T.J.K., L.M.D., I.K.M.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (R.J.Y., J.R., J.T., J.A.-P., A.I.H., S.B.T.); Department of Pat
  • Dong C; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (M.I.d., S.B., A.T., A.A.O., C.P.N., E.P., T.J.K., L.M.D., I.K.M.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (R.J.Y., J.R., J.T., J.A.-P., A.I.H., S.B.T.); Department of Pat
  • Thomas A; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (M.I.d., S.B., A.T., A.A.O., C.P.N., E.P., T.J.K., L.M.D., I.K.M.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (R.J.Y., J.R., J.T., J.A.-P., A.I.H., S.B.T.); Department of Pat
  • Omuro AA; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (M.I.d., S.B., A.T., A.A.O., C.P.N., E.P., T.J.K., L.M.D., I.K.M.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (R.J.Y., J.R., J.T., J.A.-P., A.I.H., S.B.T.); Department of Pat
  • Nolan CP; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (M.I.d., S.B., A.T., A.A.O., C.P.N., E.P., T.J.K., L.M.D., I.K.M.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (R.J.Y., J.R., J.T., J.A.-P., A.I.H., S.B.T.); Department of Pat
  • Pentsova E; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (M.I.d., S.B., A.T., A.A.O., C.P.N., E.P., T.J.K., L.M.D., I.K.M.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (R.J.Y., J.R., J.T., J.A.-P., A.I.H., S.B.T.); Department of Pat
  • Kaley TJ; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (M.I.d., S.B., A.T., A.A.O., C.P.N., E.P., T.J.K., L.M.D., I.K.M.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (R.J.Y., J.R., J.T., J.A.-P., A.I.H., S.B.T.); Department of Pat
  • Oh JH; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (M.I.d., S.B., A.T., A.A.O., C.P.N., E.P., T.J.K., L.M.D., I.K.M.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (R.J.Y., J.R., J.T., J.A.-P., A.I.H., S.B.T.); Department of Pat
  • Noeske R; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (M.I.d., S.B., A.T., A.A.O., C.P.N., E.P., T.J.K., L.M.D., I.K.M.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (R.J.Y., J.R., J.T., J.A.-P., A.I.H., S.B.T.); Department of Pat
  • Maher E; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (M.I.d., S.B., A.T., A.A.O., C.P.N., E.P., T.J.K., L.M.D., I.K.M.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (R.J.Y., J.R., J.T., J.A.-P., A.I.H., S.B.T.); Department of Pat
  • Choi C; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (M.I.d., S.B., A.T., A.A.O., C.P.N., E.P., T.J.K., L.M.D., I.K.M.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (R.J.Y., J.R., J.T., J.A.-P., A.I.H., S.B.T.); Department of Pat
  • Gutin PH; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (M.I.d., S.B., A.T., A.A.O., C.P.N., E.P., T.J.K., L.M.D., I.K.M.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (R.J.Y., J.R., J.T., J.A.-P., A.I.H., S.B.T.); Department of Pat
  • Holodny AI; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (M.I.d., S.B., A.T., A.A.O., C.P.N., E.P., T.J.K., L.M.D., I.K.M.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (R.J.Y., J.R., J.T., J.A.-P., A.I.H., S.B.T.); Department of Pat
  • Yen K; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (M.I.d., S.B., A.T., A.A.O., C.P.N., E.P., T.J.K., L.M.D., I.K.M.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (R.J.Y., J.R., J.T., J.A.-P., A.I.H., S.B.T.); Department of Pat
  • DeAngelis LM; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (M.I.d., S.B., A.T., A.A.O., C.P.N., E.P., T.J.K., L.M.D., I.K.M.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (R.J.Y., J.R., J.T., J.A.-P., A.I.H., S.B.T.); Department of Pat
  • Mellinghoff IK; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (M.I.d., S.B., A.T., A.A.O., C.P.N., E.P., T.J.K., L.M.D., I.K.M.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (R.J.Y., J.R., J.T., J.A.-P., A.I.H., S.B.T.); Department of Pat
  • Thakur SB; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (M.I.d., S.B., A.T., A.A.O., C.P.N., E.P., T.J.K., L.M.D., I.K.M.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (R.J.Y., J.R., J.T., J.A.-P., A.I.H., S.B.T.); Department of Pat
Neuro Oncol ; 18(2): 283-90, 2016 Feb.
Article em En | MEDLINE | ID: mdl-26691210
ABSTRACT

BACKGROUND:

The majority of WHO grades II and III gliomas harbor a missense mutation in the metabolic gene isocitrate dehydrogenase (IDH) and accumulate the metabolite R-2-hydroxyglutarate (R-2HG). Prior studies showed that this metabolite can be detected in vivo using proton magnetic-resonance spectroscopy (MRS), but the sensitivity of this methodology and its clinical implications are unknown.

METHODS:

We developed an MR imaging protocol to integrate 2HG-MRS into routine clinical glioma imaging and examined its performance in 89 consecutive glioma patients.

RESULTS:

Detection of 2-hydroxyglutarate (2HG) in IDH-mutant gliomas was closely linked to tumor volume, with sensitivity ranging from 8% for small tumors (<3.4 mL) to 91% for larger tumors (>8 mL). In patients undergoing 2HG-MRS prior to surgery, tumor levels of 2HG corresponded with tumor cellularity but not with tumor grade or mitotic index. Cytoreductive therapy resulted in a gradual decrease in 2HG levels with kinetics that closely mirrored changes in tumor volume.

CONCLUSIONS:

Our study demonstrates that 2HG-MRS can be linked with routine MR imaging to provide quantitative measurements of 2HG in glioma and may be useful as an imaging biomarker to monitor the abundance of IDH-mutant tumor cells noninvasively during glioma therapy and disease monitoring.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Guias de Prática Clínica como Assunto / Espectroscopia de Prótons por Ressonância Magnética / Glioma / Glutaratos / Isocitrato Desidrogenase Tipo de estudo: Guideline / Observational_studies / Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Neuro Oncol Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Guias de Prática Clínica como Assunto / Espectroscopia de Prótons por Ressonância Magnética / Glioma / Glutaratos / Isocitrato Desidrogenase Tipo de estudo: Guideline / Observational_studies / Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Neuro Oncol Ano de publicação: 2016 Tipo de documento: Article